Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 159,900 shares, an increase of 300.8% from the September 30th total of 39,900 shares. Approximately 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 3,050,000 shares, the days-to-cover ratio is presently 0.1 days.
Institutional Trading of Bluejay Diagnostics
A hedge fund recently bought a new stake in Bluejay Diagnostics stock. CVI Holdings LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned 19.69% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by hedge funds and other institutional investors.
Bluejay Diagnostics Stock Performance
BJDX stock opened at $0.11 on Friday. The firm has a market cap of $35,380.80, a PE ratio of 0.00 and a beta of 0.70. Bluejay Diagnostics has a one year low of $0.08 and a one year high of $34.24. The firm’s 50 day moving average price is $0.15 and its 200-day moving average price is $1.83.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- Industrial Products Stocks Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Do ETFs Pay Dividends? What You Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Investors Need to Know About Upcoming IPOs
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.